Drugs / MSLN STAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05344976 | Apr 2022 → Oct 2024 | — | Peking University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MSLN-STAR-T cells | “autologous-derived MSLN-STAR-T cells will be infused intravenously” NCT05344976 ↗ |
| Modality | Cell therapy | “autologous-derived MSLN-STAR-T cells” NCT05344976 ↗ |
| Route | Intravenous | “infused intravenously” NCT05344976 ↗ |